325
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Cerebrospinal Flt3 ligand correlates to tau protein levels in primary Sjögren’s syndrome

, , , , , & show all
Pages 394-399 | Accepted 23 May 2013, Published online: 10 Jul 2013

References

  • Chai J, Logigian EL. Neurological manifestations of primary Sjögren’s syndrome. Curr Opin Neurol 2010;23:509–13.
  • Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, Ferriby D, Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 2004;83:280–91.
  • Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Ann Rev Biochem 2000;69:373–98.
  • Chiba T, Yamada M, Aiso S. Targeting the JAK2/STAT3 axis in Alzheimer’s disease. Expert Opin Ther Targets 2009;13:1155–67.
  • Ko HS, Lee Y, Shin JH, Karuppagounder SS, Gadad BS, Koleske AJ, Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin’s ubiquitination and protective function. Proc Natl Acad Sci USA 2010;107:16691–6.
  • Fujita-Yoshigaki J, Matsuki-Fukushima M, Sugiya H. Inhibition of Src and p38 MAP kinases suppresses the change of claudin expression induced on dedifferentiation of primary cultured parotid acinar cells. Am J Physiol 2008;294:C774–85.
  • Koski H, Konttinen YT, Hietanen J, Tervo T, Malmstrom M. Epidermal growth factor, transforming growth factor-alpha, and epidermal growth factor receptor in labial salivary glands in Sjögren’s syndrome. J Rheumatol 1997;24:1930–5.
  • Katz J, Stavropoulos F, Cohen D, Robledo J, Stewart C, Heft M. IGF- 1 and insulin receptor expression in the minor salivary gland tissues of Sjögren’s syndrome and mucoceles – immunohistochemical study. Oral Dis 2003;9:7–13.
  • Servet-Delprat C, Arnaud S, Jurdic P, Nataf S, Grasset MF, Soulas C, Flt3+ macrophage precursors commit sequentially to osteoclasts, dendritic cells and microglia. BMC Immunol 2002;3:15.
  • Nakamori Y, Liu B, Ohishi K, Suzuki K, Ino K, Matsumoto T, Human bone marrow stromal cells simultaneously support B and T/NK lineage development from human haematopoietic progenitors: a principal role for flt3 ligand in lymphopoiesis. Br J Haematol 2012;157:674–86.
  • Sitnicka E, Brakebusch C, Martensson IL, Svensson M, Agace WW, Sigvardsson M, Complementary signaling through flt3 and interleukin-7 receptor alpha is indispensable for fetal and adult B cell genesis. J Exp Med 2003;198:1495–506.
  • Jensen CT, Kharazi S, Boiers C, Cheng M, Lubking A, Sitnicka E, FLT3 ligand and not TSLP is the key regulator of IL-7-independent B-1 and B-2 B lymphopoiesis. Blood 2008;112:2297–304.
  • Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960–8.
  • Aloisi F. Immune function of microglia. Glia 2001;36:165–79.
  • Santambrogio L, Belyanskaya SL, Fischer FR, Cipriani B, Brosnan CF, Ricciardi-Castagnoli P, Developmental plasticity of CNS microglia. Proc Natl Acad Sci USA 2001;98:6295–300.
  • Brazel CY, Ducceschi MH, Pytowski B, Levison SW. The FLT3 tyrosine kinase receptor inhibits neural stem/progenitor cell proliferation and collaborates with NGF to promote neuronal survival. Mol Cell Neurosci 2001;18:381–93.
  • Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011;69:570–80.
  • Ilzecka J. Cerebrospinal fluid Flt3 ligand level in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2006;114:205–9.
  • Tobon GJ, Renaudineau Y, Hillion S, Cornec D, Devauchelle-Pensec V, Youinou P, The Fms-like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjögren’s syndrome. Arthritis Rheum 2010;62:3447–56.
  • King GD, Muhammad AK, Curtin JF, Barcia C, Puntel M, Liu C, Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro-oncology 2008;10:19–31.
  • Xiong W, Candolfi M, Liu C, Muhammad AK, Yagiz K, Puntel M, Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial. PloS One 2010;5:e11074.
  • Whartenby KA, Calabresi PA, McCadden E, Nguyen B, Kardian D, Wang T, Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc Natl Acad Sci USA 2005;102:16741–6.
  • DeBoy CA, Rus H, Tegla C, Cudrici C, Jones MV, Pardo CA, FLT-3 expression and function on microglia in multiple sclerosis. Exp Mol Pathol 2010;89:109–16.
  • Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131–44.
  • Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554–8.
  • Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160–72.
  • Diagnostic and statistical manual of mental disorders, 3rd edn, revised. Arlington, VA: American Psychiatric Association, 1987.
  • McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44.
  • Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991;18:728–33.
  • Dehlin M, Bokarewa M, Rottapel R, Foster SJ, Magnusson M, Dahlberg LE, Intra-articular fms-like tyrosine kinase 3 ligand expression is a driving force in induction and progression of arthritis. PloS One 2008;3:e3633.
  • Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26:231–45.
  • Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjögren M, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49–52.
  • Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996;67:2013–18.
  • Rosengren LE, Wikkelso C, Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. J Neurosc Methods 1994;51:197–204.
  • Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336–45.
  • Blennow K, Fredman P, Wallin A, Gottfries CG, Langstrom G, Svennerholm L. Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio. Eur Neurol 1993;33:126–8.
  • Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord 2003;15:169–76.
  • Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 2007;78:461–4.
  • Mancuso M, Orsucci D, LoGerfo A, Calsolaro V, Siciliano G. Clinical features and pathogenesis of Alzheimer’s disease: involvement of mitochondria and mitochondrial DNA. Adv Exp Med Biol 2010;685:34–44.
  • Bazzichi L, Rossi A, Massimetti G, Giannaccini G, Giuliano T, De Feo F, Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin Exp Rheumatol 2007;25:225–30.
  • Wang H, Moser M, Schiltenwolf M, Buchner M. Circulating cytokine levels compared to pain in patients with fibromyalgia – a prospective longitudinal study over 6 months. J Rheumatol 2008;35:1366–70.
  • Wallace DJ. Is there a role for cytokine based therapies in fibromyalgia. Curr Pharm Des 2006;12:17–22.
  • Gur A, Oktayoglu P. Status of immune mediators in fibromyalgia. Curr Pain Headache Rep 2008;12:175–81.
  • Petersel DL, Dror V, Cheung R. Central amplification and fibromyalgia: disorder of pain processing. J Neurosci Res 2011;89:29–34.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.